[1] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer′s disease[J]. Lancet, 2021, 397: 1577-1590. [2] Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer′s disease[J]. Cell, 2017, 169: 1276-1290. e17. [3] Yang J, Fu Z, Zhang X, et al. TREM2 ectodomain and its soluble form in Alzheimer′s disease[J]. J Neuroinflammation, 2020, 17: 204. doi:10.1186/s12974-020-01878-2. [4] Zhou Y, Tada M, Cai Z, et al. Human early-onset dementia caused by DAP12 deficiency reveals a unique signature of dysregulated microglia[J]. Nat Immunol, 2023, 24: 545-557. [5] Piccio L, Deming Y, Del-Águila JL, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status[J]. Acta Neuropathol, 2016, 131: 925-933. [6] Reitz C, Mayeux R. TREM2 and neurodegenerative disease[J]. N Engl J Med, 2013, 369: 1564. doi:10.1056/NEJMc1306509. [7] Painter MM, Atagi Y, Liu CC, et al. TREM2 in CNS homeostasis and neurodegenerative disease[J]. Mol Neurodegener, 2015, 10: 43. doi:10.1186/s13024-015-0040-9. [8] Zhong L, Wang Z, Wang D, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2)[J]. Mol Neurodegener, 2018, 13: 15. doi:10.1186/s13024-018-0247-7. [9] Ulland TK, Song WM, Huang SCC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer′s disease[J]. Cell, 2017, 170: 649-663. e13. [10] Kober DL, Alexander-Brett JM, Karch CM, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms[J]. elife, 2016, 5: e20391. doi:10.7554/eLife.20391. [11] Greven JA, Wydra JR, Greer RA, et al. Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer′s disease ligands[J]. Mol Neurodegener, 2025, 20: 3. doi:10.1186/s13024-024-00795-9. |